Richard Burr: “Let us make sure that we are getting as much bang for our buck.”

When the Reagan revolution came to the Senate, Orrin Hatch became the Committee's Chair.

I question whether the agreements both passed and proposed reflect a good deal for patients they are designed to serve.

What does it mean for a small company when FDA misses these goals, and what does it mean to patients?

Ms. Kotagal's refusal to continue these common-sense measures speaks volumes of her lack of commitment to due process and transparency.